Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgical Oncology
Published in: Indian Journal of Surgical Oncology 1/2021

01-04-2021 | Breast Cancer | Review Article

Molecular Biology in the Breast Clinics—Current status and future perspectives

Authors: Vani Parmar, Nita S Nair, Purvi Thakkar, Garvit Chitkara

Published in: Indian Journal of Surgical Oncology | Special Issue 1/2021

Login to get access

Abstract

Breast cancer is no longer considered a single disease, and with better understanding of cancer biology, its management has evolved over the years, into a complex individualized use of therapeutics based on variable expressions of predictive and prognostic factors. With the advent of molecular and genetic research, the complexity and diversity of breast cancer cells and their ability to survive and develop resistance to treatment strategies became more evident. At the same time, targeted therapies evolved, as specific targets were discovered such as HER2 receptor, and androgen receptor. More recent is the development of immunotherapy which aims at strengthening the host immune system to identify and kill the tumor cells. In breast cancer treatment, use of molecular tests has been a target of controversies, due to their high costs and inaccessibility in limited resource situations. Research in breast cancer is also proceeding at a rapid pace, but it is important to remember that breast cancer continues to be a complex interplay of alterations at molecular and genetic level, with the variability in expressions at protein level leading to difference in behavior and responses to treatment and overall outcome. In the succeeding paragraphs, we will try to review the available evidence in literature and attempt to understand the molecular complexity of breast cancer in order to simplify the art of treating the disease and improving outcomes.
Literature
1.
Fisher B (1992) The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 52:2371–2383PubMed
2.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMed
3.
Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997e4013
4.
Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48e72
5.
6.
Ravdin PM (1996) A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 23(1 Suppl 2):43–50PubMed
7.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 80(8 Suppl IV):3–18
8.
Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991PubMed
9.
Wishart GC, Azzato EM, Greenberg DC et al (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12(1):R1PubMedPubMedCentral
10.
11.
Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low grade invasive breast carcinomas. Mod Pathol 25:556e66
12.
Palmieri C, Saji S, Sakaguchi H et al (2004) The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J MolEndocrinol 33:35e50
13.
Latta EK, Tjan S, Parkes RK, O’Malley FP (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15:1318e25
14.
Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMed
15.
Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829–1834PubMed
16.
Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMed
17.
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol2011;22:1736–1747.
18.
Sparano JA et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. NEngl J Med 379:111–121
19.
van de Vijver MJ, He YD, van't Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMed
20.
Mook S, Schmidt MK, Weigelt B et al (2010) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21:717–722PubMed
21.
Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1892PubMed
22.
Mook S, Schmidt MK, Viale G et al (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295–302PubMed
23.
24.
Filipits M, Rudas M, Jakesz R et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012–6020PubMed
25.
Ma XJ, Salunga R, Dahiya S et al (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601–2608PubMed
26.
Ma XJ, Wang Z, Ryan PD et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607–616PubMed
27.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160PubMedPubMedCentral
28.
Lænkholm AV, Jensen MB, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, Ferree S, Schaper C, Nielsen TO, Haffner T, Kibøl T (2018) PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor–positive early breast cancer. J Clin Oncol 36(8):735–740PubMed
29.
30.
Glauben Landskron, Marjorie De la Fuente, Peti Thuwajit, Chanitra Thuwajit, and Marcela A. Hermoso. Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research, Vol 2014, Article ID 149185.
31.
32.
Xuan Li, Danian Dai, Bo Chen, Hailin Tang, Xiaoming Xie, and Weidong Wei. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 Patients. Hindawi: Disease Markers Volume 2018, Article ID 9863092, 15 pages https://​doi.​org/​10.​1155/​2018/​9863092
33.
34.
35.
36.
37.
38.
Fleisher B, Clarke C, Ait-Oudhia S (2016) Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer - Targets and Therapy 8:183–197PubMedCentralPubMed
39.
Roberti MP, Arriaga JM, Bianchini M et al (2012) Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer BiolTher 13(11):1123–1140
40.
Bear HD, Tang G, Rastogi P et al (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366(4):310–320PubMedPubMedCentral
41.
Tolaney SM, Boucher Y, Duda DG et al (2015) Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. ProcNatlAcadSci U S A 112(46):14325–14330
42.
Soliman H, Khalil F, Antonia S (2014) PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 9(2):e88557PubMedPubMedCentral
43.
44.
Pande M, Bondy ML, Do KA et al (2014) Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 147(2):381–387PubMedPubMedCentral
45.
46.
Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819PubMed
47.
Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW (2014) Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One 9(9):e108405PubMedPubMedCentral
48.
Andre F, Hatzis C, Anderson K et al (2007) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13(7):2061–2067PubMed
49.
Rouzier R, Rajan R, Wagner P et al (2005) Microtubuleassociated protein tau: a marker of paclitaxel sensitivity in breast cancer. ProcNatlAcadSci USA 102(23):8315–8320
50.
Pusztai L, Jeong J-H, Gong Y et al (2009) Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J ClinOncol 27(26):4287–4292
51.
Gianni L, Esserman W, Semiglazov V et al (2014) Neo-adjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647. https://​doi.​org/​10.​1016/​S1470-2045(14)70080-4
52.
Kang SA, Guan JS, Tan HJ, Chu T et al (2018) Elevated WBP2 expression in HER2 positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy: a retrospective and multicentre study. Clin Cancer Res 28 [Epub ahead of print]
53.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284–2293PubMed
54.
Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265–7277PubMed
55.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 362(9381):362–369PubMed
56.
Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23(30):7483–7490PubMed
57.
Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J (2006) Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu–amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24(16):2428–2436PubMed
58.
Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M (2011) Multifactorial approach to predicting resistance to anthracyclines. J ClinOncol 29(12):1578–1586
59.
Slamon D, Press M (2009) Alterations in the TOP2A and HER2 genes. J Natl Cancer Inst 101(9):615–618PubMed
60.
61.
62.
Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172PubMed
63.
Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159PubMed
64.
vonMinckwitz G, Huang CS, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628
65.
Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J ClinOncol 28:1684–1691
66.
Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. JClinOncol 26:2373–2378
67.
Millar EK, Graham PH, O’Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J ClinOncol 27:4701–4708
68.
Albert JM, Gonzalez-Angulo AM, Guray M, et al: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J RadiatOncolBiolPhys 77:1296–1302, 2010
69.
Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946–951PubMed
70.
Rausei S, Rovera F, Dionigi G, Tornese D, Fachinetti A, Boni L, Dionigi R (2010) Predictors of loco-regional recurrence and cancer-related death after breast cancer surgery. Breast J 16(Suppl 1):S29–S33PubMed
71.
Cheng SH, Horng CF, West M (2006) Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J ClinOncol 24(28):4594–4602
72.
Abdulkarim BS, Cuartero J, Hanson J et al (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J ClinOncol 29:2852–2858
73.
Panoff JE, Hurley J, Takita C et al (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and postmastectomy radiation. Breast Cancer Res Treat 128:899–906PubMed
74.
Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J ClinOncol 24:3726–3734
75.
Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J (2008) Estrogen receptor, progesterone receptor, HER-2, and response to post-mastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J ClinOncol 26(9):1419e26
76.
Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH et al (2012) Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118(20):4944–4952PubMed
77.
Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J ClinOncol 27(28):4701–4708
78.
Tseng WH, Martinez SR (2011) Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol 18(1):94–103PubMed
79.
80.
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575PubMedPubMedCentral
81.
Rutgers EJ, Donker M, Straver ME et al (2013) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J ClinOncol 31(suppl; abstr LBA1001)
82.
Slamon DJ, Mackey J, Robert N, et al.Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease #13. Presented at: 30th Annual San Antonio Breast Cancer Symposium; Dec. 13–16, 2007; San Antonio.
83.
Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S, Isola J (2000) Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156(3):839–847PubMedPubMedCentral
84.
Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8(5):1107–1116PubMed
85.
Park K, Kim J, Lim S, Han S (2003) Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39(5):631–634PubMed
86.
Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106(2):181–189PubMed
87.
O’malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101(9):644–650PubMedPubMedCentral
88.
Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (20082) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. JNCI: J Natl Cancer Institut 100(1):14–20
89.
Slamon DJ, Eiermann W, Robert NJ, et al: Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04. Presented December 11, 2015.
90.
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Dent R (2009) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(3):375–379PubMed
91.
Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(23):3764–3771PubMed
92.
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145PubMedPubMedCentral
93.
Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19(11):1847–1852PubMed
94.
Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He JI (2013) Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett 5(3):983–991PubMed
95.
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117(5):1370–1380PubMedPubMedCentral
96.
Santana-Davila R, Perez EA (2010) Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 3(1):42PubMedPubMedCentral
97.
Horak CE, Lee FY, Xu L, Galbraith S, Baselga J (2009) High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J Clin Oncol 27(15_suppl):3587
98.
Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. InBreast Cancer Research and Treatment 2007 Dec 1 (Vol. 106, pp. S270-S270).
99.
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923PubMed
100.
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer discovery 2(11):1036–1047PubMedPubMedCentral
101.
Sonnenblick A, De Azambuja E, Azim HA Jr, Piccart M (2015) An update on PARP inhibitors—moving to the adjuvant setting. Nat Rev Clin Oncol 12(1):27PubMed
102.
Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly (ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134(2):649–659PubMedPubMedCentral
103.
Ratnam K, Low JA (2007) Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 13(5):1383–1388PubMed
104.
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. ClinOncol. 27(27):4536–4541
105.
Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10(20):7031–7042PubMed
106.
Mayer I, Means-Powell J, Shyr Y, Arteaga C. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer.
107.
Greenberg S, Rugo HS (2010) Triple-negative breast cancer: role of antiangiogenic agents. The Cancer Journal 16(1):33–38PubMed
108.
Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 27(15S):551
109.
Minami CA, Chung DU, Chang HR (2011) Management options in triple-negative breast cancer. Breast Cancer: Basic Clin Res 5:BCBCR–S6562
110.
Dowsett M (2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8(3):191–195PubMed
111.
Jones A (2003) Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why? Ann Oncol 14(12):1697–1704PubMed
112.
De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D’Agostino D, Caputo F, Cancello G, Montagna E (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11(13):4741–4748PubMed
113.
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W (2002) Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20(6):1467–1472PubMed
114.
García-Becerra R, Santos N, Díaz L, Camacho J (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14(1):108–145PubMedPubMedCentral
115.
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85–95PubMed
116.
Antoniotti S, Maggiora P, Dati C, De Bortoli M (1992) Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28(2–3):318–321PubMed
117.
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10(12):2435–2446PubMed
118.
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546PubMed
119.
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529–5537PubMed
120.
Azim HA Jr, Piccart MJ (2010) Simultaneous targeting of estrogen receptor and HER2 in breast cancer. Expert Rev Anticancer Ther 10(8):1255–1263PubMed
121.
Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R (2015) Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer 15(1):442PubMedPubMedCentral
122.
Lousberg L, Collignon J, Jerusalem G (2016) Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 8(6):429–449PubMedPubMedCentral
123.
Weigelt B, Mackay A, A’hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet Oncology 11(4):339–349PubMed
124.
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100(14):8418–8423PubMedPubMedCentral
125.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7(1):96PubMedPubMedCentral
126.
Ioannidis JP, Allison DB, Ball CA, Coulibaly I, Cui X, Culhane AC, Falchi M, Furlanello C, Game L, Jurman G, Mangion J (2009) Repeatability of published microarray gene expression analyses. Nat Genet 41(2):149PubMed
127.
Abstract number 90, presented at UAE Cancer Congress 2018, Dubai
128.
Cuzick J et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278PubMed
129.
Andre F, Pusztai L (2006) Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3(11):621–632 ReviewPubMed
130.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65. https://​doi.​org/​10.​1186/​bcr2124CrossRefPubMedPubMedCentral
131.
Metadata
Title
Molecular Biology in the Breast Clinics—Current status and future perspectives
Authors
Vani Parmar
Nita S Nair
Purvi Thakkar
Garvit Chitkara
Publication date
01-04-2021
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue Special Issue 1/2021
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-019-00954-1

Other articles of this Special Issue 1/2021

Indian Journal of Surgical Oncology 1/2021 Go to the issue

Original Article

TRF2 Overexpression at the Surgical Resection Margin: A Potential Predictive Biomarker in Oral Squamous Cell Carcinoma for Recurrence

Original Article

Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients

Original Article

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario

Original Article

mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in Gastric Cancer: a Pilot Study

Original Article

Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies

Original Article

Negative Prognostic Implication of TERT Promoter Mutations in Human Papillomavirus–Negative Tonsillar Squamous Cell Carcinoma Under the New 8th AJCC Staging System